$BDX

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

BD (NYSE: BDX) said Gary Sorsher will become executive vice president and chief quality officer effective Sept. 8. He previously served as chief quality officer at Edwards Lifesciences. BD also announced Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years at the company.

Original reporting
Published Aug 17, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire — source image
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

This is primarily an organizational change within BD’s quality leadership, with potential medium-term implications for quality system execution but no immediate operational or financial disclosures.

02

Market read

Quality leadership succession at BD is disclosed, but without new quality incidents, regulatory outcomes, or financial guidance.

03

What to watch

Future impact depends on whether Sorsher’s prior approach at Edwards Lifesciences translates into measurable quality KPIs, audit outcomes, or changes to manufacturing/process controls at BD.

Relevance 4/10Novelty 4/10Timing: effective September 8, with retirement of current SVP in October

Background

BD announced a new chief quality officer and the retirement of its current global head of quality.

Company-level read

Ticker impact

$BDXNeutralMedium confidence
Context

BD named Gary Sorsher executive vice president and chief quality officer effective September 8, replacing retiring quality leadership in October.

Expected impact

Likely limited near-term impact unless investors later connect the change to quality incidents, audits, or product performance.

Evidence & confidence

The article is a corporate leadership appointment and retirement notice with no disclosed incidents, guidance, or regulatory findings; market reaction should be modest and contingent on future operational updates.

Market effects

Highlights ongoing focus on MedTech quality systems and patient safety, but provides no new sector-wide regulatory or enforcement signal.

None indicated.

None indicated beyond BD’s global quality organization scope.

Counterpoint

Investors may discount the appointment as routine succession, since no new quality problems, recalls, or regulatory actions are mentioned.

Key entities

  • BD

    Becton, Dickinson and Company, medical technology company announcing quality leadership changes.

  • Gary Sorsher

    Named executive vice president and chief quality officer at BD, effective September 8.

  • Jeffrey Silvestri

    Senior vice president, global head of quality at BD, retiring in October.

  • Tom Polen

    BD chairman, CEO and president commenting on the quality leadership transition.

Related articles

$BDXLow

BD trial reaches 274 patients studying breast implant scar tissue

BD (BDX) announced its STANCE clinical trial for GalaFLEX LITE™ Scaffold in breast revision surgery has treated 274 patients, surpassing a key milestone. The trial, comparing the scaffold to conventional surgery, aims to support a future FDA application for a new breast indication. BD's P4HB technology has over a decade of clinical use in soft tissue support.

$BDXMed

Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?

Becton, Dickinson and Company (BDX) medical technology shares have outperformed the S&P 500 and the iShares U.S. Medical Devices ETF over the past year and YTD. After Q3 results on Aug. 6, BDX reported adjusted EPS of $3.23 vs $3.14 expected, revenue of $5.0B vs $4.9B, and full-year adjusted EPS guidance of $12.62 to $12.72. Analysts rate it a “Moderate Buy” with a mean target of $187.33 and a Citigroup target of $208.

$MDLNMed

Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products - Medline (NASDA

Medline said regulatory guidance followed its corrective actions for surgical convenience kits whose components were affected by a Becton Dickinson recall. The alert cites BD lot 4032183 ChloraPrep Clear 1 mL and lot 4073005 FREPP Clear 1.5 mL applicators, with compromised sterile seals and possible Aspergillus contamination. Medline reported no severe injuries or deaths as of Aug 3. MDLN shares were $35.71, up 0.61%.

$BDXMedAI 8/10

BD (BDX) Q3 2026 Earnings Call Transcript

BD reported Q3 fiscal 2026 results for “New BD” after its Life Sciences spin-off. Revenue was $4.98B, up 4.4% FX-neutral; adjusted diluted EPS was $3.23, up 4.9%. Adjusted operating margin was 24.9% after 110 bps tariff impact. Full-year adjusted EPS guidance raised to $12.62-$12.72 midpoint; revenue growth guided toward high end of low-single-digit FX-neutral range.

$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.